Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Javle, Milind ^a   Li, Yanan ^a   Tan, Dongfeng ^a   Dong, Xiaoqun ^a   Chang, Ping ^a   Kar, Siddhartha ^a   Li, Donghui ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR MARKER; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PANCREAS SURGERY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMAD4 GENE; TGF BETA1 GENE; TGF BETA2 GENE; TGF BETA3 GENE; TGF BETAR1 GENE; TGF BETAR2 GENE; TRANSFORMING GROWTH FACTOR BETA1 BLOOD LEVEL; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC VARIABILITY; TGF BETA GENE; TGF BETA RECEPTOR 1 GENE; TGF BETA RECEPTOR 2 GENE; TUMOR BIOPSY; METABOLISM; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84908097616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085942     Document Type: Article

References (32)

1. Tian M, Schiemann WP (2009) The TGF-beta paradox in human cancer: an update. Future Oncology 5: 259-271.
2. Bernabeu C, Lopez-Novoa JM, Quintanilla M (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochimica et Biophysica Acta 1792: 954-973.
3. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399-405.
4. Joshi A, Cao D (2010) TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Frontiers in Bioscience 15: 180-194.
5. Wakefield LM, Hill CS (2013) Beyond TGF: roles of other TGF superfamily members in cancer. Nature Reviews Cancer. 13: 328-341.
6. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
7. Ijichi H, Ikenoue T, Kato N, Mitsuno Y, Togo G, et al. (2001) Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells. Biochem Biophys Res Commun 289: 350-357. (Pubitemid 33141060)
8. Truty MJ, Urrutia R (2007) Basics of TGF-beta and pancreatic cancer. Pancreatology 7: 423-435.
9. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, et al. (2006) Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146. (Pubitemid 44790628)
10. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, et al. (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27: 1806-1813.
11. Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, et al. (2011) Genetic variants in TGF-beta pathway are associated with ovarian cancer risk. PLoS One 6: e25559.
12. Scollen S, Luccarini C, Baynes C, Driver K, Humphreys MK, et al. (2011) TGF-beta signaling pathway and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev 20: 1112-1119.
13. Fang F, Yu L, Zhong Y, Yao L (2010) TGFB1 509 C/T polymorphism and colorectal cancer risk: a meta-analysis. Med Oncol 27: 1324-1328.
14. Bhayal AC, Prabhakar B, Rao KP, Penchikala A, Ayesha Q, et al. (2011) Role of transforming growth factor-beta1-509 C/T promoter polymorphism in gastric cancer in south Indian population. Tumour Biol 32: 1049-1053.
15. Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, et al. (2011) Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 32: 1050-1056.
16. Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, et al. (2007) Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102: 2696-2707. (Pubitemid 350179330)
17. Li D, Suzuki H, Liu B, Morris J, Liu J, et al. (2009) DNA repair gene polymorphisms and risk of pancreatic cancer. Clin Cancer Res 15: 740-746.
18. Dong X, Jiao L, Li Y, Evans DB, Wang H, et al. (2009) Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol 27: 1592-1599.
19. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, et al. (1993) Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856. (Pubitemid 24002804)
20. Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, et al. (1993) Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 53: 2704-2707. (Pubitemid 23180499)
21. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, et al. (1996) DPC4 gene in various tumor types. Cancer Res 56: 2527-2530. (Pubitemid 26170688)
22. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
23. Hua Z, Zhang YC, Hu XM, Jia ZG (2003) Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol 9: 2764-2767. (Pubitemid 38054456)
24. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, et al. (2011) Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29: 3037-3043.
25. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104: 1440-1451.
26. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nature genetics 29: 117-129. (Pubitemid 32952643)
27. Wang Y, Deng B, Tang W, Liu T, Shen X (2013) TGF-beta1 secreted by hepatocellular carcinoma induces the expression of the Foxp3 gene and suppresses antitumor immunity in the tumor microenvironment. Digestive diseases and sciences 58: 1644-1652.
28. Fukuchi M, Miyazaki T, Fukai Y, Nakajima M, Sohda M, et al. (2004) Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer. Clin Cancer Res 10: 2738-2741. (Pubitemid 38509149)
29. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, et al. (2003) Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 39: 454-461. (Pubitemid 36173689)
30. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, et al. (2001) Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92: 2985-2992. (Pubitemid 33136192)
31. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, et al. (2001) Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19: 2856-2864. (Pubitemid 32538195)
32. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528. (Pubitemid 46175758)